Lupin Partners with Tenpoint to Expand YUVEZZI™ Eye Drop Reach in Europe
Event summary
- Lupin's VISUfarma secures exclusive rights to commercialize YUVEZZI™ in the EU, UK, Switzerland, Norway, and Iceland.
- Tenpoint Therapeutics will receive regulatory and commercial milestone payments plus tiered royalties based on net sales.
- YUVEZZI™ is the first and only once-daily dual-agent eye drop approved for presbyopia, a condition affecting 2 billion people globally.
- Tenpoint has already submitted an MMA in the UK via the MHRA's International Recognition Procedure.
- Lupin's CEO Vinita Gupta highlights the partnership as a strategic move to strengthen its vision care franchise in Europe.
The big picture
This partnership underscores Lupin's strategy to expand its specialty care business through innovative therapies, addressing significant unmet needs in the rapidly growing presbyopia vision management segment. The deal also highlights the increasing trend of regional partnerships to accelerate the commercialization of novel ophthalmic treatments. With YUVEZZI™ already approved in the U.S., this move positions Lupin to capture a significant share of the European market, where presbyopia affects a substantial and aging population.
What we're watching
- Regulatory Progress
- The pace at which Tenpoint secures regulatory approvals in other key regions will determine the global reach of YUVEZZI™.
- Market Penetration
- Whether Lupin can effectively leverage its existing European distribution network to drive YUVEZZI™ adoption.
- Revenue Impact
- How tiered royalty structures and milestone payments will affect Tenpoint's financial performance.
Related topics